Top Authors

• Most frequent coverage on SNTA

• 
  Ohad Hammer (176 followers)

  • Morphosys: A Biotech Rule Breaker (Part 2) (Mon, Mar 30)
  • 'When There's Blood in the Streets', Buy Biotech Stocks (Fri, Oct 10)
  • Immunogen's Wild Swings Due to Lack of Information at ASCO (Mon, Jul 14)

  More by Ohad Hammer on SNTA »
• 
  Alan Brochstein (712 followers)

  • Cancer Stocks Hammered Once Again (Tue, Jun 26)
  • Cancer Stocks Slide Again (Mon, Jun 18)
  • Cancer Stocks Plunge Following ASCO Meeting (Mon, Jun 11)

  More by Alan Brochstein on SNTA »
• 
  Mike Havrilla (1944 followers)

  • 1H09 Catalysts for 4 Healthcare Stocks (Thu, Jan 8)
  • New Emerging Biotech and Pharma Company Index (Sun, Nov 23)

  More by Mike Havrilla on SNTA »

• Most followed authors on SNTA

• 
  Mike Havrilla (1944 followers)

  • 1H09 Catalysts for 4 Healthcare Stocks (Thu, Jan 8)
  • New Emerging Biotech and Pharma Company Index (Sun, Nov 23)

  More by Mike Havrilla on SNTA »
• 
  Alan Brochstein (712 followers)

  • Cancer Stocks Hammered Once Again (Tue, Jun 26)
  • Cancer Stocks Slide Again (Mon, Jun 18)
  • Cancer Stocks Plunge Following ASCO Meeting (Mon, Jun 11)

  More by Alan Brochstein on SNTA »
• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on SNTA »

• Newest authors on SNTA

• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on SNTA »
• 
  Mark Cifra (30 followers)

  • Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly (Thu, Apr 2)

  More by Mark Cifra on SNTA »
• 
  Michael Becker (165 followers)

  • Chink in the Biotechnology Armor (Sun, Mar 1)

  More by Michael Becker on SNTA »

• Most commented on SNTA

• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on SNTA »
• 
  Ohad Hammer (176 followers)

  • Morphosys: A Biotech Rule Breaker (Part 2) (Mon, Mar 30)
  • 'When There's Blood in the Streets', Buy Biotech Stocks (Fri, Oct 10)
  • Immunogen's Wild Swings Due to Lack of Information at ASCO (Mon, Jul 14)

  More by Ohad Hammer on SNTA »
• 
  Alan Brochstein (712 followers)

  • Cancer Stocks Hammered Once Again (Tue, Jun 26)
  • Cancer Stocks Slide Again (Mon, Jun 18)
  • Cancer Stocks Plunge Following ASCO Meeting (Mon, Jun 11)

  More by Alan Brochstein on SNTA »